Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

BACKGROUND: This study aimed to define the maximally tolerated dose (MTD) of sunitinib combined with two different infusion schedules of ifosfamide. METHODS: Patients with advanced solid tumours, good performance score, good organ function, and no standard therapy available were eligible. Continuous...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamberg, P, Steeghs, N, Loos, W J, van de Biessen, D, den Hollander, M, Tascilar, M, Verweij, J, Gelderblom, H, Sleijfer, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883699/
https://www.ncbi.nlm.nih.gov/pubmed/20485286
http://dx.doi.org/10.1038/sj.bjc.6605696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883699/
https://www.ncbi.nlm.nih.gov/pubmed/20485286
http://dx.doi.org/10.1038/sj.bjc.6605696

Ejemplares similares